<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB04955</drugbank-id>
  <name>Pumactant</name>
  <description>Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).</description>
  <cas-number>258856-56-3</cas-number>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3059</ref-id>
        <pubmed-id>12797502</pubmed-id>
        <citation>Babu KS, Woodcock DA, Smith SE, Staniforth JN, Holgate ST, Conway JH: Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J. 2003 Jun;21(6):1046-9.</citation>
      </article>
      <article>
        <ref-id>A3060</ref-id>
        <pubmed-id>10791521</pubmed-id>
        <citation>Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, Ward Platt MP: Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet. 2000 Apr 22;355(9213):1387-92.</citation>
      </article>
      <article>
        <ref-id>A3061</ref-id>
        <pubmed-id>15294062</pubmed-id>
        <citation>Young PM, Thompson J, Woodcock D, Aydin M, Price R: The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy. J Aerosol Med. 2004 Summer;17(2):123-8.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in asthma, lung injury, and surgical adhesions.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Pumactant is known as a lung (pulmonary) surfactant. Surfactants are wetting agents which coat the surface of the air sacs (alveoli) and reduce surface tension in the lungs. This helps to inflate and expand the air sacs during breathing and prevents their collapse. Surfactants are normally produced naturally in the lungs. A failure by the lungs to do this results in a life threatening disorder known as respiratory distress syndrome, where the lungs become stiff, uninflatable and make breathing extremely difficult. This commonly occurs in premature babies, where their under-developed lungs are incapable of producing surfactants. Pumactant is given directly into the lung through a tube (endotracheal administration), to replace the natural surfactant and therefore aids breathing in premature babies.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">ALEC</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Membrane Lipids</category>
      <mesh-id>D008563</mesh-id>
    </category>
    <category>
      <category>Pulmonary Surfactants</category>
      <mesh-id>D011663</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347909857</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pumactant</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>